Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
NMR Research Unit, Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London (UCL) Queen Square Institute of Neurology, London, UK.
Ann Clin Transl Neurol. 2022 Jul;9(7):1090-1094. doi: 10.1002/acn3.51595. Epub 2022 May 19.
Remyelination efficiency declines with advancing age in animal models, but this has been harder to demonstrate in people with multiple sclerosis. We show that bexarotene, a putatively remyelinating retinoid-X receptor agonist, shortened the visual evoked potential latency in patients with chronic optic neuropathy aged under 42 years only (with the effect diminishing by 0.45 ms per year of age); and increased the magnetization transfer ratio of deep gray matter lesions in those under 43 years only. Addressing this age-related decline in human remyelination capacity will be an important step in the development of remyelinating therapies that work across the lifespan.
髓鞘再生效率随年龄增长而下降，这在动物模型中已经得到证实，但在多发性硬化症患者中则更难证明。我们发现，倍他罗汀（一种潜在的髓鞘再生视黄酸受体激动剂）仅能缩短 42 岁以下慢性视神经病变患者的视觉诱发电位潜伏期（其效果随年龄每增加 1 岁而减少 0.45 毫秒）；并且仅能增加 43 岁以下患者深部灰质病变的磁化传递率。解决人类髓鞘再生能力随年龄下降的问题，将是开发跨生命周期起作用的髓鞘再生疗法的重要一步。
